<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03993236</url>
  </required_header>
  <id_info>
    <org_study_id>ROSETTA-Stroke</org_study_id>
    <nct_id>NCT03993236</nct_id>
  </id_info>
  <brief_title>Study on Rosuvastatin+Ezetimibe and Rosuvastatin for LDL-C Goal in Patients With Recent Ischemic Stroke</brief_title>
  <official_title>Moderate-intensity Rosuvastatin Plus Ezetimibe Versus High-intensity Rosuvastatin for Target LDL-C Goal Achievement in Patients With Recent Ischemic Stroke: a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Keun-Sik Hong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ewha Womans University Seoul hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Myongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul St. Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chung-Ang University Hosptial, Chung-Ang University College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Inje University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized clinical trial for the comparison of the efficacy and safety of
      moderate-intensity rosuvastatin plus ezetimibe versus high-intensity rosuvastatin for target
      LDL-C goal achievement in patients with recent ischemic stroke
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare the efficiency and safety on the target LDL-C goal
      achievement between rosuvastatin 10 mg plus ezetimibe 10 mg (rosuvastatin/ezetimibe 10/10 mg)
      once daily versus rosuvastatin 20 mg once daily in patients with recent ischemic stroke.

      The target LDL-C goal achievement rate in patients with recent ischemic stroke has not been
      well studied. In particular, no clinical studies have been conducted comparing the efficacy
      and safety of low-dose rosuvastatin plus ezetimibe with high-dose rosuvastatin single agent
      for achieving target LDL-C levels.

      In this trial, the investigators aim to compare the efficacy of the target LDL-C achievement
      between rosuvastatin 10 mg plus ezetimibe 10 mg (rosuvastatin/ezetimibe 10/10 mg) and
      rosuvastatin 20 mg in patients with recent ischemic stroke.

      For this trial, more than 292 patients (584 total) per group will be enrolled.

      Subjects who were satisfied with the inclusion/exclusion criteria of this trial and who
      agreed to participate in the clinical trial in writing were randomly assigned to a 1:1 ratio
      in the experimental group (the low-dose combination of rosuvastatin plus ezetimibe) and
      comparator group (high-dose rosuvastatin).

      The duration of administration of the drug for clinical trials is 90 days (±14 days), and the
      efficacy and safety evaluation parameters are compared with baseline.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2019</start_date>
  <completion_date type="Anticipated">November 12, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 12, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of subjects with LDL-C decreased more than 50% at 90days (±14 days) compared to Baseline</measure>
    <time_frame>Baseline, Visit 4(Day 90)</time_frame>
    <description>The percentage of subjects with LDL-C decreased more than 50% at 90days (±14 days) compared to Baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with LDL-C less than 70 mg/dL at 90 days(±14 days)</measure>
    <time_frame>Baseline, Visit 4(Day 90)</time_frame>
    <description>Percentage of subjects with LDL-C less than 70 mg/dL at 90 days(±14 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects with LDL-C decreased more than or less than 70 mg/dL at 90 days(±14 days)</measure>
    <time_frame>Baseline, Visit 4(Day 90)</time_frame>
    <description>The percentage of subjects with LDL-C decreased more than or less than 70 mg/dL at 90 days(±14 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The decrement of LDL-C at 90 days (±14 days) compared to baseline LDL-C (absolute difference and change)</measure>
    <time_frame>Baseline, Visit 4(Day 90)</time_frame>
    <description>The decrement of LDL-C at 90 days (±14 days) compared to baseline LDL-C (absolute difference and change)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects achieved multiple lipid level (Total-C &lt; 200mg/dL, LDL-C &lt; 70mg/dL and triglyceride &lt; 150mg /dL)</measure>
    <time_frame>Baseline, Visit 4(Day 90)</time_frame>
    <description>The percentage of subjects achieved multiple lipid level (Total-C &lt; 200mg/dL, LDL-C &lt; 70mg/dL and triglyceride &lt; 150mg /dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular event rates including stroke (ischemic or hemorrhagic), coronary artery(myocardial infarction or coronary vascular reperfusion) and death related to vascular disease.</measure>
    <time_frame>Baseline to Visit 4(up to 90 days)</time_frame>
    <description>Cardiovascular event rates including stroke (ischemic of hemorrhagic), coronary artery(myocardial infarction or coronary vascular reperfusion) and death related to vascular disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Death of all causes.</measure>
    <time_frame>Baseline to Visit 4(up to 90 days)</time_frame>
    <description>Number of Death of all causes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with newly diagnosed diabetes.</measure>
    <time_frame>Visit 4(Day 90)</time_frame>
    <description>Number of subjects with newly diagnosed diabetes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue scale measured by Fatigue Severity Scale.</measure>
    <time_frame>Screening, Visit 4(Day 90)</time_frame>
    <description>Fatigue scale measured by Fatigue Severity Scale. (The Fatigue Severity Scale is a 9-item scale which measures the severity of fatigue and its effect on a person's activity and lifestyle in patients with a variety of disorders. A 9-item questionnaire with questions related to how fatigue interferes with certain activities and rates its severity. The Fatigue Severity Scale scores range from 9 to 63, with higher scores indicating a greater fatigue severity.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of rhabdomyolysis</measure>
    <time_frame>Baseline to Visit 4(up to 90 days)</time_frame>
    <description>Incidence of rhabdomyolysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious liver dysfunction</measure>
    <time_frame>Baseline to Visit 4(up to 90 days)</time_frame>
    <description>Incidence of serious liver dysfunction (AST or ALT increase more than three times from baseline)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">584</enrollment>
  <condition>Stroke, Ischemic</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin/Ezetimibe 10/10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental group is orally administered with rosuvastatin 10 mg plus ezetimibe 10 mg combination once daily for 90 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin 20mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The comparator group is orally administered with rosuvastatin 20 mg single agent once daily for 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental: Rosuvastatin/Ezetimibe 10</intervention_name>
    <description>Rosuvastatin/Ezetimibe 10/10mg
orally administered once daily for 90 days</description>
    <arm_group_label>Rosuvastatin/Ezetimibe 10/10mg</arm_group_label>
    <other_name>Rosuzet tab 10/10 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Comparator: Rosuvastatin 20mg</intervention_name>
    <description>Rosuvastatin 20mg
orally administered once daily for 90 days</description>
    <arm_group_label>Rosuvastatin 20mg</arm_group_label>
    <other_name>Suvast tab 20mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with recent ischemic stroke who meet both 1) and 2) criteria below. 1)
             Patients with acute ischemic stroke confirmed by DWI(diffusion-weighted imaging)

             This is satisfied by meeting at least one of the following two criteria:

               1. Patients who sustained stroke symptoms for more than 24 hours and had acute
                  ischemic lesions on DWI.

               2. Patients with acute ischemic lesions in DWI who had improved symptoms within 24
                  hours.

                  2) Patients with ischemic stroke within 90 days.

          2. Statin therapy indicated according to the recommendations of the 2014 American Heart
             Association/American Stroke Association guidelines.

             This is accomplished by meeting at least one of the following three criteria:

               1. Patients with ischemic stroke due to arteriosclerosis and LDL-C ≥ 100 mg / dL.
                  (Class I; Level of Evidence B)

               2. Patients with ischemic stroke due to arteriosclerosis and LDL-C &lt;100 mg / dL.
                  (Class I; Level of Evidence C)

               3. Patients who require statin therapy due to other associated atherosclerotic
                  cardiovascular disease. (Class I; Level of Evidence A).

          3. Patients without statin dose within 28 days before ischemic stroke.

          4. Patients who measured baseline LDL-C levels after an ischemic stroke. This is
             satisfied by meeting at least one of the following two criteria:

               1. Patients who had a baseline LDL-C level before the onset of a recent ischemic
                  stroke and started statin therapy.

               2. Patients hospitalized with acute ischemic stroke who had baseline LDL-C levels
                  after initiation of statin therapy should meet both of the following conditions:

                    1. Patients with LDL-C levels measured within 3 days after initiation of statin
                       therapy

                    2. Patients in whom randomization and administration of the study drug can be
                       administered within 7 days after baseline LDL-C measurement.

          5. Adults over 19 years.

          6. Those who voluntarily agreed in writing to the trial.

        Exclusion Criteria:

          1. Planned vascular intervention before the end of trial

          2. Significant hepatic dysfunction (Aspartate Aminotransferase or Alanine
             Aminotransferase &gt;120 IU/L)

          3. Allergy or contraindication to rosuvastatin or ezetimibe

          4. Alcohol or drug addiction

          5. Pregnancy or breast-feeding

          6. Severe anemia: Hb level &lt;10 g/dL for men and &lt;9 g/dL for women

          7. Bleeding diathesis: platelet count &lt;100,000/μl or prothrombin time International
             Normalized Ratio &gt; 1·7

          8. Inability or unwillingness to comply with study-related procedures

          9. Employees of the investigator or study center, with direct involvement in the current
             study

         10. Women unwilling to continue contraception during the study period

         11. Participation in other clinical trials within three-month

         12. Malignancy or other serious medical conditions with a life expectancy &lt;6 months

         13. Treatment with protease inhibitors or cyclosporine

         14. Patients with severe renal impairment (creatinine clearance &lt;30 mL / min)

         15. Other reasons for ineligibility judged by investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keun-Sik Hong, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, Inje University Ilsan Paik Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Keun-Sik Hong, MD., PhD.</last_name>
    <phone>82-31-910-7277</phone>
    <email>nrhks@paik.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan-Si</city>
        <state>Gyeonggi-Do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin-Man Jung, MD., PhD.</last_name>
      <email>sodium75@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hallym University Medical Center</name>
      <address>
        <city>Anyang-si</city>
        <state>Gyeonggi-Do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mi-Sun Oh, MD., PhD.</last_name>
      <email>iyyar@hallym.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Myongji Hospital</name>
      <address>
        <city>Goyang-Si</city>
        <state>Gyeonggi-Do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong-Ho Park, MD., PhD.</last_name>
      <email>neurocraft.jhp@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inje University Ilsan Paik Hospital</name>
      <address>
        <city>Ilsan</city>
        <state>Gyeonggi-Do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keun-Sik Hong, MD, Phd</last_name>
      <phone>82-31-910-7277</phone>
      <email>nrhks@paik.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hopital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kwang-Yeol Park, MD., PhD.</last_name>
      <email>sbaram1@cau.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Seoul hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tae-Jin Song, MD., PhD.</last_name>
      <email>knstar@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chi-Kyung Kim, MD., PhD.</last_name>
      <email>ckkim7@korea.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyung-Hee University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung-Hyuk Heo, MD., PhD.</last_name>
      <email>shheo73@khu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center, Sungkyunkwan University School of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oh-Young Bang, MD., PhD.</last_name>
      <email>ohyoung.bang@samsung.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tae-Jung Kim, MD.,PhD.</last_name>
      <email>ttae35@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul St Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ja-Seong Koo, MD., PhD.</last_name>
      <email>carotidstroke@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyo-Suk Nam, MD., PhD.</last_name>
      <email>hsnam@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 17, 2019</study_first_submitted>
  <study_first_submitted_qc>June 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2019</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Inje University</investigator_affiliation>
    <investigator_full_name>Keun-Sik Hong</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Stroke, Ischemic</keyword>
  <keyword>Rosuvastatin</keyword>
  <keyword>Ezetimibe</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

